COSA 2020: First-Line Pembrolizumab + Platinum-Based Chemotherapy + Lenvatinib Shows Promise in Metastatic NSCLC
A safety run-in precedes the efficacy evaluation.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.